Trillium Therapeutics Inc. logo
Trillium Therapeutics Inc. TRIL

Trillium Therapeutics Inc. Financial Ratios 2011-2026 | TRIL

Annual Financial Ratios Trillium Therapeutics Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-18.6 -2.5 -0.7 -1.8 -1.2 -3.6 -4.5 -5.1 - -

P/S

7441.5 838.4 - - - - - - - -

EV/EBITDA

-14.0 -2.7 -0.3 -1.5 0.0 1.6 -2.6 2.8 - -

PEG

0.32 0.08 0.02 -0.13 -0.01 0.13 4.09 0.06 - -

P/B

3.9 -618.8 0.8 1.3 0.8 0.6 2.4 0.6 - -

P/CF

-48.4 -4.1 -0.8 -3.8 -1.9 -3.7 -7.7 -8.7 - -

ROE %

-21.28 24775.00 -107.44 -76.32 -72.62 -17.17 -53.01 -12.65 - -

ROA %

-19.73 -163.82 -80.59 -63.52 -63.35 -16.36 -45.70 -12.22 - -

ROCE %

-22.00 -298.30 -117.47 -68.26 -73.88 -24.55 -53.42 -12.51 - -

DSO

2335.5 962.5 - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Trillium Therapeutics Inc., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 9.13 -0.76 % $ 591 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.91 2.42 % $ 6.69 M chinaChina
Edesa Biotech Edesa Biotech
EDSA
$ 15.52 -2.39 % $ 49.6 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.47 1.19 % $ 3.72 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 2.24 0.9 % $ 62.5 M usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
$ 2.26 0.22 % $ 144 M usaUSA
Galapagos NV Galapagos NV
GLPG
$ 28.07 0.75 % $ 2.69 B belgiumBelgium
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.2 3.6 % $ 6.83 B spainSpain
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 31.01 -0.13 % $ 1.78 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 8.44 - $ 76.2 M usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.95 -1.77 % $ 152 M germanyGermany
Immuron Limited Immuron Limited
IMRN
$ 0.83 3.44 % $ 6.55 M australiaAustralia
Incyte Corporation Incyte Corporation
INCY
$ 98.87 -0.23 % $ 19.3 B usaUSA
InMed Pharmaceuticals InMed Pharmaceuticals
INM
$ 0.71 1.28 % $ 1.74 M canadaCanada
INmune Bio INmune Bio
INMB
$ 1.35 1.5 % $ 33.4 M usaUSA
Innoviva Innoviva
INVA
$ 23.13 0.35 % $ 1.56 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 104.54 2.92 % $ 27.2 B germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Jaguar Health Jaguar Health
JAGX
$ 7.55 -4.13 % $ 17.6 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
$ 26.67 -0.02 % $ 1.44 B britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 1.43 -4.03 % $ 235 M franceFrance
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.15 0.49 % $ 260 M israelIsrael
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
$ 13.24 6.56 % $ 1.75 B australiaAustralia
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
$ 223.98 -0.39 % $ 4.1 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.22 7.69 % $ 5.3 M israelIsrael
Liquidia Corporation Liquidia Corporation
LQDA
$ 38.39 0.62 % $ 3.3 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.08 0.74 % $ 436 M usaUSA